Tucson, Arizona / January 5, 2026 — Aspiro Therapeutics will be attending JPM Week 2026 in San Francisco, where the team will be meeting with investors, industry leaders, and potential partners focused on innovation in respiratory medicine.
During the week, Aspiro will engage in discussions around the evolving treatment landscape for obstructive lung diseases, including asthma and COPD, and the growing need for disease-modifying therapies that address underlying biology rather than symptoms alone.
In parallel with JPM Week, Aspiro will participate in events hosted by BLPN, an invite-only, member-led club bringing together life science dealmakers during the conference week.
Aspiro is advancing an inhaled, CC16-inspired therapy designed to modify disease progression in obstructive lung diseases and remains focused on progressing toward IND-enabling milestones.
